Can a weekly drug combo outsmart resistant lymphoma?
NCT ID NCT01703949
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 pilot study tests whether giving brentuximab vedotin weekly, alone or with nivolumab, can help people with CD30+ lymphoma whose cancer stopped responding to the standard every-3-week dosing. The study enrolls 28 adults with relapsed or refractory Hodgkin or non-Hodgkin lymphoma. The goal is to see if the new schedule can shrink tumors in at least 20% (with brentuximab alone) or 40% (with the combination) of patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brentuximab vedotin (a drug that targets cancer cells) and nivolumab (an immunotherapy that helps the immune system attack cancer)
What this could lead to
If successful, this could offer a new treatment option for people with CD30+ lymphoma whose cancer no longer responds to standard brentuximab vedotin dosing.
What could go wrong
This is a small, early-phase pilot study with only 28 participants. The response rate targets are modest (20-40%), and the results may not apply to all patients. Side effects from the drugs are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States